Rationale: Epstein-Barr virus mucocutaneous ulcers (EBVMCUs) were officially recognized as a clinicopathologic entity in the 2017 revision of the World Health Organization classification, which often occurs in the elderly or in immunosuppressive condition presented as an isolated ulcerative lesion. EBVMCUs are defined as "shallow, sharply circumscribed, mucosal or cutaneous ulcers with underlying polymorphous infiltration." It mostly involves oral mucosa, but some appear in skin or gastrointestinal tract. Typically, patients with EBVMCUs display a slow disease progression and may even undergo spontaneous regression.

Patient Concerns: This report describes the case of a 76-year-old woman who visited our outpatient clinic with the chief complaint of inflammation and ulceration on lower labial, lower right lingual gingiva seemed like acute necrotizing ulcerative gingivitis, and malignancy.

Diagnoses: She was diagnosed with EBVMCU after tissue biopsy.

Interventions: Since most oral ulcerations usually appear in nonspecific form, it is important to check thoroughly for any underlying immunosuppressive systemic conditions and laboratory test results in case of viral infection. But she has no remarkable underlying immunosuppressive disorder.

Outcomes: For this patient, she was initially diagnosed with EBVMCU and showed spontaneous healing, but then relapsed after 4 to 6 months. The patient was re-diagnosed as EBV-positive diffuse large B-cell lymphoma (EBV-positive DLBCLs) after re-biopsy.

Lessons: EBVMCU shows similar symptoms to malignant lesions or acute necrotizing ulcerative gingivitis but shows spontaneous healing. However, in case of EBV-positive DLBCLs, failing to detect and treat the disease in its early stages can lead to a fatal outcome. Thus, this case report highlights the differential diagnosis and appropriate treatment of EBVMCU and EBV-positive DLBCLs.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11309666PMC
http://dx.doi.org/10.1097/MD.0000000000037243DOI Listing

Publication Analysis

Top Keywords

ebv-positive dlbcls
12
differential diagnosis
8
ebv-positive diffuse
8
diffuse large
8
large b-cell
8
b-cell lymphoma
8
case report
8
acute necrotizing
8
necrotizing ulcerative
8
ulcerative gingivitis
8

Similar Publications

Primary thyroid lymphomas comprise largely extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (EMZL) and diffuse large B-cell lymphoma (DLBCL), followed by follicular lymphoma (FL). They commonly develop from a background of Hashimoto's thyroiditis (HT), where dysregulated immune responses trigger autoreactive infiltrates and drive clonal B-cell evolution. To understand how these lymphomas and their relapse evolve, we investigated 10 cases by mutation profiling, including five with metachronous lymphomas [primary lymphoma (EMZL = 4, DLBCL = 1) with local relapse (EMZL = 3, DLBCL = 2)], one composite EMZL and Epstein-Barr virus (EBV)-positive DLBCL, and four lymphomas (EMZL = 3, FL = 1) with prior or subsequent biopsy showing HT.

View Article and Find Full Text PDF

The bi- or multinucleated Reed-Sternberg cell (RS) is the diagnostic cornerstone of Epstein-Barr Virus (EBV)-positive and EBV-negative classical Hodgkin lymphoma (cHL). cHL is a germinal center (GC)-derived B-cell disease. Hodgkin cells (H) are the mononuclear precursors of RS.

View Article and Find Full Text PDF
Article Synopsis
  • Immunochemotherapy shows limited effectiveness for Epstein-Barr virus-positive diffuse large B-cell lymphoma (EBV + DLBCL) that doesn’t respond to standard treatments, prompting the exploration of PD-1 inhibitors plus chemotherapy as a potential alternative.
  • A study involving six adults with refractory EBV + DLBCL treated with PD-1 inhibitors and chemotherapy as a second-line option yielded an 83% objective response rate and a 67% complete remission rate after a median follow-up of 20 months.
  • These promising results suggest that combining PD-1 inhibitors with chemotherapy could be an effective treatment for resistant EBV + DLBCL, but larger clinical trials are needed to confirm these findings.
View Article and Find Full Text PDF

Bruton's tyrosine kinase inhibitors have been demonstrated preliminary efficacy in diffuse large B-cell lymphoma (DLBCL). To compare the safety and efficacy of zanubrutinib plus rituximab and lenalidomide (ZR2) and R-CHOP-like for elderly patients with newly diagnosed DLBCL, we conducted this single-center prospective study. Patients were treated with 6 cycles of ZR2 or R-CHOP-like regimen for the first-line treatment.

View Article and Find Full Text PDF
Article Synopsis
  • * A meta-analysis of Ago-CLIP datasets from various B cell lymphomas revealed functional interactions between BART miRNAs and over 50 protein-coding transcripts, affecting processes like B cell differentiation, cell cycle regulation, and tumor suppression.
  • * Ectopic expression of BART miRNAs in EBV-negative Burkitt lymphomas caused significant transcriptional changes, suggesting their critical role in influencing molecular characteristics of EBV-associated lymphomas.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!